Boehringer Ingelheim and OSE Immunotherapeutics Announce Expansion of Two Solid Tumor Programs
Expanded collaboration seeks to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases.
Boehringer Ingelheim and OSE Immunotherapeutics have announced a major expansion of their already-existing partnership. The duo will be adding two new projects to develop first-in-class treatments—the first focusing on broadening the therapeutic evaluation of an already partnered asset to reach more patients and the second being a new asset acquisition.1
The first project involves anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371, which are being investigated in Phase I clinical studies in advanced solid tumors. In addition to current research, the development of these compounds will now be pursued in cardio-renal-metabolic (CRM) diseases.
The second project is the launch of a new preclinical program, which will develop immune-cell activating treatments based on OSE’s cis-targeting anti-PD1/cytokine platform, acquired by Boehringer Ingelheim.
“We are very pleased to expand our pipeline of potential first-in-class CRM disease therapies, as well as our pipeline of first-in-class T-cell based anti-cancer therapies,” Clive R. Wood, corporate senior vice president and global head of discovery research at Boehringer Ingelheim said in a press release. “The expansion of our partnership with OSE reflects our joint mission to improving patient outcomes in two of the biggest threats to global health.”
“We are excited about adding two highly innovative new development programs to our fruitful collaboration with Boehringer Ingelheim,” Nicolas Poirier, CEO of OSE Immunotherapeutics said in the press release. “We look forward to working with the scientists at Boehringer Ingelheim on the new development programs that have the potential to bring new breakthrough therapy options to patients with CRM diseases and cancer.”
Reference
1. Boehringer Ingelheim and OSE Immunotherapeutics expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases. News release. May 22, 2024. Accessed May 23, 2024. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/partnership-first-class-cancer-and-crm-treatments
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
